What Menopause Is Actually Doing to the Heart
The estrogen model gave medicine a framework. New research suggests it was never the complete picture and the capital implications haven't caught up.
A few years ago, I sat in a doctor’s office and that experience marked the beginning of my journey into women’s health investing. Three years ago, I started writing what I thought was a report. It became a book about the gaps and opportunities in women’s health. Today, that book, The Billion Dollar Blindspot is available for pre-order.
This week on Signal Not Noise - The $11.75B Sun Pharma / Organon deal is being read as good news for women's health. But is it really?
Weekly capital intelligence on women's health investing, delivered directly to your inbox. 30% off through May.
Jane is 52. Her cholesterol is slightly elevated. Her blood pressure has crept up. Her sleep is fragmented, her energy inconsistent, her body unfamiliar in quiet, disorienting ways. Sitting across from her physician, she hears a version of a sentence that has been repeated, in slightly different forms, to millions of women before her. Nothing is acutely wrong. Nothing demands urgency. It is, she is told, part of the transition.
Menopause.
The framing is clinical, almost reassuring. Her hormones are declining, her risk is increasing, and this is expected. Manage your numbers, adjust your lifestyle, monitor over time. It sounds contained, even understood. And for decades, that is precisely how medicine, and by extension capital, has treated it: as a hormonal shift, a loss of protection, a gradual and predictable increase in risk.
But what if that framing was never the full story? What if what we have been calling “risk” is not simply the absence of something, but the beginning of something else entirely?
For most of modern medicine, estrogen has been cast as the central actor in women’s cardiovascular health. It was a model built for clarity. Estrogen conferred protection; menopause removed it. The downstream effects; rising rates of heart disease, metabolic dysfunction, vascular changes were interpreted as consequences of that loss.
From a systems perspective, it made sense. From a funding perspective, it was efficient. It enabled interventions that were measurable, testable, and scalable. Hormone replacement therapies, lipid-lowering drugs, glucose management, lifestyle interventions. Each mapped neatly onto existing clinical pathways and, critically, into established investment categories.
The issue is not that this model is wrong. The issue is that it is incomplete. And in both science and markets, incomplete models do more than leave gaps in understanding. They define what gets measured, what gets funded, and what remains invisible.
A recent line of research emerging from the Fralin Biomedical Research Institute begins to complicate this picture. Led by Sumita Mishra and published in the journal Cells, the work does not claim to have identified a single new mechanism behind the rise in cardiovascular risk after menopause. Instead, it reframes the question itself. Rather than asking only what happens when estrogen declines, it asks what that decline does to the systems that regulate the body over time.
The answer points toward epigenetics; the layer of biological control that determines when genes turn on or off without altering the underlying DNA sequence. In this view, menopause is not just a hormonal event. It is a regulatory event. A shift that may alter how genes governing cardiovascular function, metabolism, and inflammation are expressed across interconnected systems and over extended periods of time.
This is a subtle but consequential shift in perspective. It is the difference between removing a protective shield and rewiring the system beneath it. It suggests that what we are observing after menopause is not simply deterioration, but a form of reprogramming, one that unfolds across multiple biological domains at once.
At this stage, the science remains early. Much of the mechanistic evidence comes from laboratory and preclinical studies. Longitudinal human data is still limited. The causal pathways are not yet fully mapped, and the magnitude of these effects is not precisely quantified. This is not a finished story, nor a definitive explanation. But even in its current form, it begins to expose something more structural: not just a gap in biological understanding, but a gap in how that understanding has been organized.
Epigenetics itself is not new. It has been studied extensively, particularly in oncology, where gene regulation is central to disease progression and treatment. But its application to cardiometabolic health—especially in the context of women’s biology—has been comparatively limited because they sat outside the primary focus of inquiry.
And inquiry follows structure. It follows funding priorities, institutional incentives, and the categories through which we define disease. Breast cancer has a defined category, established funding streams, and a clear research mandate. Cardiovascular disease, too, is one of the most heavily funded and studied areas in medicine.
But the intersection of hormonal transition, gene regulation, metabolic dysfunction, and cardiovascular risk in women sits awkwardly between them. It does not belong cleanly to any single category. And what does not belong is often what does not get funded.
There is a broader pattern here. When biological systems become more complex than the frameworks we have built to study them, we do not immediately expand the framework. We simplify the biology. We isolate variables, prioritize what can be measured, and construct models that are tractable, even if they are partial. Those models then become the foundation not only for clinical practice, but for entire investment landscapes.
The estrogen model was one such construct. It enabled decades of progress, but it also constrained the scope of inquiry. It made certain questions easier to ask, and others easier to ignore.
The emerging epigenetic perspective does not replace that model, but it stretches it. It introduces a layer of complexity that does not fit neatly into existing categories. If menopause-related cardiovascular risk is mediated not only by hormone levels but by changes in gene regulation across metabolic and inflammatory systems, then the way we think about intervention begins to shift. It is no longer sufficient to replace or supplement what has been lost. We may need to understand and eventually target the regulatory pathways that have been altered.
This is where the implications extend beyond medicine into capital allocation. When a problem spans multiple domains, it often falls between mandates. It can appear too niche for generalist funds, too complex for single-vertical specialists, and too early for large-scale pharmaceutical investment. The result is not a lack of interest, but a lack of alignment. Capital flows most efficiently to what it can categorize. What it cannot easily classify is often treated as peripheral even when it is central.
We have seen this pattern in other areas of women’s health. Alzheimer’s disease, where women represent a disproportionate share of cases, has long been studied through frameworks that did not fully integrate hormonal and metabolic transitions.
Osteoporosis has often been reduced to a question of bone density rather than understood as part of a broader system of aging and hormonal regulation. Autoimmune diseases, many of which disproportionately affect women, continue to challenge models built around more linear cause-and-effect relationships.
In each case, the biology is complex, interconnected, and resistant to simplification. And in each case, funding has struggled to keep pace with that complexity.
What this new line of research begins to expose is not just a biological insight, but a structural one. We have built disease categories that make certain patterns visible and others peripheral. We have trained both clinicians and investors to recognize opportunity within those categories. And we have, often unintentionally, treated anything that does not fit as an exception. But women’s biology is not the exception. It is the system.
Heart disease remains the leading cause of death for women. This is not new. What is less well understood is why the risk accelerates so sharply during and after menopause, and why our existing frameworks have only partially explained it. The hormonal model gave us part of the answer. Epigenetics may be pointing toward another layer. There will likely be more.
The question, then, is not whether this research provides a definitive explanation. The question is what it reveals about the way we have been asking the question in the first place. Because when the underlying model is incomplete, the opportunity it obscures is not marginal. It is systemic. And the most valuable opportunities in markets are rarely the ones no one has seen. They are the ones everyone has seen, but just through the wrong lens.
On 28 May, I’m hosting a private conversation with some of the people who have lived this arc; operators who have built and exited in women’s health, and an investor who has backed multiple companies in the space. We will be talking about what it actually takes to build in this category, what the reimbursement and adoption curve looks like from the inside, and where the capital opportunity sits right now.
It is not a panel. It is a practitioner conversation and the kind that usually happens behind closed doors. If you want to be in the room, you can request an invitation below.
Disclaimer & Disclosure
This content is for informational and educational purposes only. It does not constitute financial, investment, legal, or medical advice, or an offer to buy or sell any securities. Opinions expressed are those of the author and may not reflect the views of affiliated organisations. Readers should seek professional advice tailored to their individual circumstances before making investment decisions. Investing involves risk, including potential loss of principal. Past performance does not guarantee future results.
If menopause is not just a hormonal transition but a system-level reprogramming, what else are we still misclassifying and therefore mispricing in women’s health?
I can't take estrogen at all, not even s tiny dose, because it causes migraines for me. I em extremely interested to hear more about this research. I often wonder about our female ancestors who lived long and healthy lives well into their 80s and 90s - how were they able to do that before HRT?!